We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Tenaya Therapeutics Inc. is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The company's product platform consist Gene Therapy, Cellular Regeneration and Precision Medicine. Tenaya Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.
- Recent TNYA Stock Price: $4.25
- Yearly Gain for TNYA stock: -36.85%
- Market Cap for TNYA stock: $333.70M
- P/E Ratio for TNYA stock: -2.53
Will TNYA's stock price go up? Is there an accurate TNYA stock forecast available?
TipRanks.com reports that Tenaya Therapeutics, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $23.25. The target pricing ranges from a high TNYA forecast of $40 down to a low forecast of $16. Tenaya Therapeutics, Inc. (TNYA)’s last closing stock price was $4.25 which would put the average price target at 447.06% upside.
In addition, TradingView issued a rating for TNYA stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on TNYA stock.
Other analysts covering TNYA include:
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $18 on 1 day ago
- Whitney Ijem of Canaccord Genuity issued a Buy rating with the price target of $16 on 1 day ago
- Cory Jubinville, PhD of LifeSci Capital issued a Buy rating with the price target of $19 on 1 day ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $40 on 1 day ago
If you are wondering if TNYA is a good stock to buy, here are 3rd party ratings for TNYA stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 37% (92 out of 250)
What is the sentiment on the street regarding Tenaya Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for TNYA stock: Bullish
- Blogger Consensus for TNYA stock:
- Media Buzz for TNYA stock: Sell
- Insider Signal for TNYA stock: Balanced
- Investor Sentiment for TNYA stock: Positive
- Hedge Fund signal for TNYA stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on TNYA stock including scouring the social networks like TNYA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TNYA stock chart >>
Summary: Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif.
- Recent SGMT Stock Price: $4.75
- Yearly Gain for SGMT stock: -70.22%
- Market Cap for SGMT stock: $151.59M
- P/E Ratio for SGMT stock: -1.79
Will SGMT's stock price go up? Is there an accurate SGMT stock forecast available?
TipRanks.com reports that Sagimet Biosciences Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $32.25. The target pricing ranges from a high SGMT forecast of $48 down to a low forecast of $23. Sagimet Biosciences Inc. (SGMT)’s last closing stock price was $4.75 which would put the average price target at 578.95% upside.
In addition, TradingView issued a rating for SGMT stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on SGMT stock.
Other analysts covering SGMT include:
- Ritu Baral of TD Cowen issued a Buy rating with the price target of n/a on 17 hours ago
- Andrea Tan of Goldman Sachs issued a Buy rating with the price target of $23 on 17 hours ago
- Jonathan Wolleben of JMP Securities issued a Buy rating with the price target of $48 on 1 day ago
- Thomas Smith of Leerink Partners issued a Buy rating with the price target of $26 on 1 month ago
If you are wondering if SGMT is a good stock to buy, here are 3rd party ratings for SGMT stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 37% (92 out of 250)
What is the sentiment on the street regarding Sagimet Biosciences Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for SGMT stock: Bullish
- Blogger Consensus for SGMT stock:
- Media Buzz for SGMT stock: Neutral
- Insider Signal for SGMT stock: Buying
- Investor Sentiment for SGMT stock: Negative
- Hedge Fund signal for SGMT stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on SGMT stock including scouring the social networks like SGMT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SGMT stock chart >>
Summary: Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA.
- Recent CMPX Stock Price: $1.60
- Yearly Gain for CMPX stock: -51.07%
- Market Cap for CMPX stock: $220.14M
- P/E Ratio for CMPX stock: -4.57
Will CMPX's stock price go up? Is there an accurate CMPX stock forecast available?
TipRanks.com reports that Compass Therapeutics, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $9.25. The target pricing ranges from a high CMPX forecast of $7 down to a low forecast of $10. Compass Therapeutics, Inc. (CMPX)’s last closing stock price was $1.60 which would put the average price target at 478.13% upside.
In addition, TradingView issued a rating for CMPX stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on CMPX stock.
Other analysts covering CMPX include:
- Stephen Willey of Stifel Nicolaus issued a Buy rating with the price target of $10 on 2 days ago
- Maury Raycroft of Jefferies issued a Buy rating with the price target of $7 on 3 days ago
- Andrew Berens of Leerink Partners issued a Buy rating with the price target of $10 on 3 days ago
If you are wondering if CMPX is a good stock to buy, here are 3rd party ratings for CMPX stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 37% (92 out of 250)
What is the sentiment on the street regarding Compass Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for CMPX stock: Bearish
- Blogger Consensus for CMPX stock:
- Media Buzz for CMPX stock: Sell
- Insider Signal for CMPX stock: Buying
- Investor Sentiment for CMPX stock: Negative
- Hedge Fund signal for CMPX stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on CMPX stock including scouring the social networks like CMPX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CMPX stock chart >>
Summary: Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States.
- Recent OVID Stock Price: $3.28
- Yearly Gain for OVID stock: -6.43%
- Market Cap for OVID stock: $231.91M
- P/E Ratio for OVID stock: -4.43
Will OVID's stock price go up? Is there an accurate OVID stock forecast available?
TipRanks.com reports that Ovid Therapeutics Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $8.75. The target pricing ranges from a high OVID forecast of $9 down to a low forecast of $11. Ovid Therapeutics Inc. (OVID)’s last closing stock price was $3.28 which would put the average price target at 166.77% upside.
In addition, TradingView issued a rating for OVID stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on OVID stock.
Other analysts covering OVID include:
- Michael Higgins of Ladenburg Thalmann & Co. issued a Buy rating with the price target of $7 on 1 day ago
- Thomas Shrader of BTIG issued a Buy rating with the price target of $11 on 2 days ago
- Francois Brisebois of Oppenheimer issued a Buy rating with the price target of $8 on 2 days ago
If you are wondering if OVID is a good stock to buy, here are 3rd party ratings for OVID stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 37% (92 out of 250)
What is the sentiment on the street regarding Ovid Therapeutics Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for OVID stock: Bearish
- Blogger Consensus for OVID stock:
- Media Buzz for OVID stock: Sell
- Insider Signal for OVID stock: Selling
- Investor Sentiment for OVID stock: Negative
- Hedge Fund signal for OVID stock: High Risk
The stock market is extremely volatile, and you need to do your own research on OVID stock including scouring the social networks like OVID StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for OVID stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================